Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling

Cancer Research

Volumn 74, Issue 20, 2014, Pages 5690-5699

  Van Noort, Vera ^a,b   Schölch, Sebastian ^c   Iskar, Murat ^a   Zeller, Georg ^a   Ostertag, Kristina ^d   Schweitzer, Christine ^c   Werner, Kristin ^c   Weitz, Jürgen ^c   Koch, Moritz ^c   Bork, Peer ^a,e  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ENILCONAZOLE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; IMIDAZOLE DERIVATIVE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CIRCULATING TUMOR CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MECHANISM; GENE EXPRESSION PROFILING; IN VITRO STUDY; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PREDICTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR EMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMANS; CITALOPRAM; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; HCT116 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; MICE, INBRED NOD; NEOPLASTIC CELLS, CIRCULATING; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908108434     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3540     Document Type: Article

References (47)

1. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
2. Iorio F, Tagliaferri R, di Bernardo D. Identifying network of drug mode of action by gene expression profiling. J Comput Biol 2009;16:241-51.
3. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3:96ra76.
4. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011;3:96ra77.
5. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011;13:627-38.
6. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013;3:1364-77.
7. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. Drug-induced regulation of target expression. PLoS Comput Biol 2010;6.
8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
9. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
10. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375:1030-47.
11. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
12. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010;138:1714-26.
13. Pantel K, Riethdorf S. Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol 2009;6:190-1.
14. Steinert G, Scholch S, Koch M, Weitz J. Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg 2012;397:535-42.
15. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progressionfree survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
16. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014;74:1694-704.
17. van der Bij GJ, Oosterling SJ, Beelen RH, Meijer S, Coffey JC, van Egmond M. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg 2009;249:727-34.
18. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007;7:54-60.
19. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF, et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011;39:D1005-10.
20. Butte AJ, Chen R. Finding disease-related genomic experiments within an international repository: first steps in translational bioinformatics. AMIA Annu Symp Proc 2006:106-10.
21. Dudley JT, Butte AJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pac Symp Biocomput 2009:27-38.
22. Pacini C, Iorio F, Goncalves E, Iskar M, Klabunde T, Bork P, et al. DvD: an R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 2013;29:132-4.
23. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad SciU S A 2005;102:15545-50.
25. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
26. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiationinduced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003;63:3755-63.
27. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
28. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 2006;7:123.
29. Qu XA, Rajpal DK. Applications of Connectivity Map in drug discovery and development. Drug Discov Today 2012;17:1289-98.
30. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-12.
31. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99:1729-34.
32. Ganepola GA, Mazziotta RM, Weeresinghe D, Corner GA, Parish CJ, Chang DH, et al. Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors. Clin Exp Metastasis 2010;27:1-9.
33. Rousset N, Vonarx V, Eleouet S, Carre J, Kerninon E, Lajat Y, et al. Effects of photodynamic therapy on adhesion molecules and metastasis. J Photochem Photobiol B 1999;52:65-73.
34. Wu H, Liang X, Fang Y, Qin X, Zhang Y, Liu J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed Pharmacother 2008;62:613-21.
35. Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 2010;62:194-9.
36. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115:3861-3.
37. Wang PS, Chou FS, Porchia L, Saji M, Pinzone JJ. Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells. Mol Carcinog 2008;47:905-15.
38. Aizawa J, Sakayama K, Kamei S, Kidani T, Yamamoto H, Norimatsu Y, et al. Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer 2010;10:51.
39. Steffan JJ, Cardelli JA. Thiazolidinediones induce Rab7-RILP-MAPKdependent juxtanuclear lysosome aggregation and reduce tumor cell invasion. Traffic 2010;11:274-86.
40. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun. N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999;18:1345-56.
41. Wang H, Zhang H, Tang L, Chen H, Wu C, Zhao M, et al. Resveratrol inhibits TGF-beta1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology 2013;303:139-46.
42. Coras R, Holsken A, Seufert S, Hauke J, Eyupoglu IY, Reichel M, et al. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 2007;6:1745-54.
43. Zhou B, Buckley ST, Patel V, Liu Y, Luo J, Krishnaveni MS, et al. Troglitazone attenuates TGF-beta1-induced EMT in alveolar epithelial cells via a PPARgamma-independent mechanism. PLoS ONE 2012;7:e38827.
44. Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, et al. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin Cancer Res 2001;7:2573-80.
45. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.
46. Rahbari NN, Bork U, Kircher A, Nimitz T, Scholch S, Kahlert C, et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol 2012;19:2195-202.
47. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.